PMC:7274968 / 3342-3537 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"44","span":{"begin":22,"end":30},"obj":"Species"}],"attributes":[{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For high-risk disease patients diagnosed during the pandemic, radiotherapy combined with ADT was the preferred treatment option recommended by the local tumorboards in 18/22 of the centers (82%)."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T35","span":{"begin":168,"end":170},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T36","span":{"begin":171,"end":173},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"}],"text":"For high-risk disease patients diagnosed during the pandemic, radiotherapy combined with ADT was the preferred treatment option recommended by the local tumorboards in 18/22 of the centers (82%)."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":89,"end":92},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_40799"}],"text":"For high-risk disease patients diagnosed during the pandemic, radiotherapy combined with ADT was the preferred treatment option recommended by the local tumorboards in 18/22 of the centers (82%)."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T29","span":{"begin":0,"end":195},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For high-risk disease patients diagnosed during the pandemic, radiotherapy combined with ADT was the preferred treatment option recommended by the local tumorboards in 18/22 of the centers (82%)."}